Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Amgen’s Aranesp for Anemia Fails to Help Heart Patients

Don't Miss Out —
Follow us on:

Jan. 16 (Bloomberg) -- Amgen Inc.’s anemia drug Aranesp didn’t keep heart failure patients alive longer or out of the hospital, according to the results of a large study that found no new safety issues with the drug.

The trial, begun in 2006, followed 2,278 heart failure patients who also had anemia and received either Aranesp or a placebo. The study didn’t meet its main goal of slowing time to death or hospital admission for worsening heart failure, Thousand Oaks, California-based Amgen said today in a statement.

There were “no new safety findings identified in the study,” Amgen, the world’s largest biotechnology company, said in the statement. Full results from the study will be presented at a future medical meeting, the company said.

Aranesp is approved for treating anemia in kidney disease patients and some cancer patients. It is part of a class of red blood cell stimulating drugs that can increase the risk of death, heart attack, stroke, or tumor progression or recurrence in cancer patients, according to a boxed warning on the drug’s label. The warning about heart risk was added in 2007, Ashleigh Koss, an Amgen spokeswoman, said in an e-mail.

Sales of the drug were $2.3 billion in 2011 after reaching $4.1 billion in 2006.

To contact the reporter on this story: Robert Langreth in New York at rlangreth@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.